Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Australian Vintage is a leading publicly traded Australian wine company, owner of brands such as McGuigan Wines and Tempus Two. The company has recently undergone leadership changes and strategic acquisitions to expand its global footprint. It reported FY2023/24 revenue of A$261 million (~US$175.7 million), with underlying EBITS up 24% but an overall net loss due to challenging market conditions[1]. In 2025, it acquired international rights to the MadFish brand to strengthen its UK presence and diversify its portfolio[7][9].
The business has no clinical or therapeutic programs; all activities are in winemaking, branding, distribution, and beverage innovation.
Recent financials show mixed results with declining sales in some periods but improved cash performance through cost control and new product launches like Poco Vino and Lemsecco[1][10].
Leadership transitioned from Craig Garvin back to Tom Dusseldorp as CEO in April 2025 after a period of restructuring[1].
The company's strategy focuses on global expansion via acquisition (e.g., MadFish), innovation in lighter varietal wines, and operational efficiency.
No evidence exists for involvement in pharmaceuticals or biotechnology.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Australian Vintage.